Nippon Shinyaku Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nippon Shinyaku Co., Ltd.
CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as Beijing shipping millions of doses around the world.
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Chinese officials do not expect the new strain of coronavirus emerging in the UK to impact the efficacy of inactivated virus vaccines on the cusp of conditional approval. Meanwhile, a new plant is under construction in China for domestically developed mRNA vaccines.
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- NS Pharma, Inc.